

<b>Study Title</b>	A Phase 1/2, Open-Label, Dose-Escalation Trial Of GEN3013 In Patients With Relapsed, Progressive Or Refractory B-Cell Lymphoma
<b>Protocol Number</b>	GCT3013-01
<b>Sponsor</b>	Genmab
<b>Contact</b>	Li Hoon Lai, Oncology Research Team Leader at <a href="mailto:lihoonlai@cabrini.com.au">lihoonlai@cabrini.com.au</a>

<b>Study Type</b> <i>Treatment</i>	<b>Study Phase</b> <i>Phase 1/2</i>	<b>Recruitment Status</b> <i>Open</i>	<b>Lead Oncologist</b> <i>Dr. Kirsten Herbert</i>
---------------------------------------	--	--	--

## Participation Eligibility

*Participant eligibility for a trial may include age, gender, type and stage of disease, and previous or current treatments and health complications. Every trial has specific inclusion and exclusion criteria and these may differ from trial to trial. The inclusion and exclusion guidelines identify who can and cannot participate in this trial. A brief explanation of this study including the inclusion and exclusion criteria is available at this public domain website*

<https://www.clinicaltrials.gov/ct2/show/NCT03625037?term=genmab&cond=B-cell+Lymphoma&cntry=AU&draw=2&rank=2>

*If you need assistance understanding the eligibility criteria, you or your doctor can contact the study team*

